We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+10.77%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.78B
AUM Growth
+$316M
Cap. Flow
+$35.3M
Cap. Flow %
0.93%
Top 10 Hldgs %
64.41%
Holding
33
New
1
Increased
14
Reduced
7
Closed
1

Top Buys

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$33.6M
2
ARGX icon
argenx
ARGX
+$25.3M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$23.1M
4
NKTR icon
Nektar Therapeutics
NKTR
+$18.2M
5
TSRO
TESARO, Inc.
TSRO
+$17.8M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$31.7M
2
CELG
Celgene Corp
CELG
+$30M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$26.6M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$18.1M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$15.5M

Sector Composition

Rank Sector Weight
1 Healthcare 96.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$8.93B
$447M 11.83%
8,666,334
– –
NBIX icon
2
Neurocrine Biosciences
NBIX
$18.2B
$388M 10.28%
3,158,090
-159,663
-5% -$18.1M
CELG
3
DELISTED
Celgene Corp
CELG
$267M 7.07%
2,984,298
-340,000
-10% -$30M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$123B
$264M 6.99%
1,370,445
-30,000
-2% -$5.34M
INCY icon
5
Incyte
INCY
$25.4B
$263M 6.96%
3,808,322
+50,000
+1% +$3.43M
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$183M 4.84%
1,314,428
-30,000
-2% -$3.76M
AGIO icon
7
Agios Pharmaceuticals
AGIO
$2.08B
$170M 4.49%
2,197,931
– –
SAGE
8
DELISTED
Sage Therapeutics
SAGE
$151M 4%
1,071,373
– –
GILD icon
9
Gilead Sciences
GILD
$165B
$151M 3.99%
1,954,596
-420,000
-18% -$31.7M
HALO icon
10
Halozyme
HALO
$9.88B
$150M 3.97%
8,247,860
– –
ESPR
11
DELISTED
Esperion Therapeutics
ESPR
$146M 3.85%
3,282,964
+100,000
+3% +$4.59M
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$38.3B
$120M 3.17%
1,370,538
+230,000
+20% +$23.1M
RDUS
13
DELISTED
Radius Health, Inc.
RDUS
$117M 3.1%
6,590,276
+389,363
+6% +$8.81M
TSRO
14
DELISTED
TESARO, Inc.
TSRO
$114M 3.03%
2,931,802
+505,000
+21% +$17.8M
MYOV
15
DELISTED
Myovant Sciences Ltd.
MYOV
$94.7M 2.51%
3,567,882
+60,000
+2% +$1.36M
AKCA
16
DELISTED
Akcea Therapeutics Inc
AKCA
$83.6M 2.21%
2,386,471
-97,600
-4% -$2.95M
REGN icon
17
Regeneron Pharmaceuticals
REGN
$72.9B
$80.8M 2.14%
200,000
-70,000
-26% -$26.6M
WVE icon
18
Wave Life Sciences
WVE
$1.12B
$69.3M 1.83%
1,385,002
+247,117
+22% +$11.1M
ICPT
19
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$69M 1.82%
545,719
– –
MGNX icon
20
MacroGenics
MGNX
$233M
$64.1M 1.7%
2,990,412
+330,000
+12% +$7.03M
ARGX icon
21
argenx
ARGX
$55.2B
$55.7M 1.47%
734,739
+285,690
+64% +$25.3M
VYGR icon
22
Voyager Therapeutics
VYGR
$181M
$53.4M 1.41%
2,822,641
+290,000
+11% +$5.56M
NKTR icon
23
Nektar Therapeutics
NKTR
$2.39B
$51.5M 1.36%
56,333
+21,333
+61% +$18.2M
EXEL icon
24
Exelixis
EXEL
$13.9B
$49.4M 1.31%
2,785,000
+1,725,000
+163% +$33.6M
ITCI
25
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$47.7M 1.26%
2,200,000
– –
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 0.35% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q3 2018 Portfolio in Review

As of Q3 2018, BB Biotech held 33 positions worth $3.78B, up 9.1% from $3.46B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

BB Biotech's Q3 2018 filing shows 1 new, 14 increased, 7 reduced and 1 closed positions. Its largest new stake was Scholar Rock: 189,957 shares worth $4.89M. The largest sale was Gilead Sciences, an estimated $31.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier.

  • BB Biotech's largest Q3 2018 buy was Scholar Rock: 189,957 shares worth $4.89M.
  • BB Biotech added most to Exelixis in Q3 2018, an estimated $33.6M increase.
  • BB Biotech's biggest Q3 2018 reduction was Gilead Sciences, cutting an estimated $31.7M.
  • BB Biotech fully exited Five Prime Therapeutics, Inc. in Q3 2018, selling an estimated $15.5M.
  • BB Biotech's ten largest holdings make up 64% of its $3.78B portfolio in Q3 2018.
  • BB Biotech opened 1 new position and closed 1 in Q3 2018.
  • BB Biotech's portfolio value rose 9.1% quarter-over-quarter to $3.78B.

Based on BB Biotech's 13F filing for Q3 2018, filed 9 Nov 2018.